Answers are grounded in this paper and cite their sources.
Advanced hepatocellular carcinoma (HCC) is increasingly managed with combinations of locoregional therapies and systemic immunotherapy or targeted therapy, yet the optimal sequencing of these modalities remains undefined. This retrospective cohort study evaluated the impact of prior transarterial chemoembolization (TACE) on outcomes after palliative radiotherapy (RT) and the contribution of post-RT systemic immunotherapy and targeted therapy to survival in advanced HCC. A total of 82 patients with TNM stage III/IV HCC receiving palliative RT (2022–2025) were categorized by prior TACE exposure (Prior-TACE, n=37; Non-prior TACE, n=45). Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier estimates and multivariate Cox models. In unadjusted analysis, the Non-prior TACE group demonstrated superior PFS (HR 0.47, 95% CI: 0.28–0.78, p=0.0037) and OS (HR 0.53, 95% CI: 0.28–0.98, p=0.0459). After multivariate adjustment, absence of prior TACE remained independently associated with improved PFS (adjusted HR=0.56, 95% CI: 0.33–0.95, p=0.032) but not OS (adjusted HR=0.73, 95% CI: 0.36–1.48, p=0.378). Independent predictors of OS included Child-Pugh class B (HR=3.22, p=0.039), TNM stage IV (HR=2.60, p=0.027) and receipt of post-RT targeted therapy (HR=0.25, p=0.003). Safety profiles were comparable between groups. In this real-world cohort, survival after palliative RT was predominantly determined by baseline liver function, tumor stage and incorporation of subsequent targeted therapy, while prior TACE independently influenced PFS. These findings inform the rational integration of locoregional therapy with systemic therapy and warrant prospective validation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: